|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
EBSCO_ocn978248730 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
170321s2017 nyua ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d EBLCP
|d OCLCQ
|d OCLCF
|d AGLDB
|d IGB
|d AUW
|d BTN
|d MHW
|d INTCL
|d SNK
|d G3B
|d S8I
|d S8J
|d STF
|d D6H
|d OCLCQ
|d OCLCO
|d OCLCQ
|
| 019 |
|
|
|a 979062587
|
| 020 |
|
|
|a 9781536102987
|q (electronic bk.)
|
| 020 |
|
|
|a 1536102989
|q (electronic bk.)
|
| 020 |
|
|
|z 9781536102772
|
| 035 |
|
|
|a (OCoLC)978248730
|z (OCoLC)979062587
|
| 050 |
|
4 |
|a RC918.D53
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.462
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Diabetic nephropathy :
|b from bench to bedside /
|c Mingxi Li and Jianling Tao, editors.
|
| 264 |
|
1 |
|a New York :
|b Nova Science Publishers, Inc.,
|c 2017.
|
| 300 |
|
|
|a 1 online resource :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Nephrology research and clinical developments
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Vendor-supplied metadata.
|
| 505 |
0 |
|
|a Preface; New Progress in Diabetic Nephropathy and Local Micro Inflammation; Abstract; Introduction; Diabetic Nephropathy and Local Inflammation; Classic Inflammation in DN; Abnormal Gene Regulation and Local Inflammation in Diabetic Nephropathy; Inflammasome and DN Inflammation; Conclusion; References; Current Findings in The Use of Proteomics Technology for the Diagnosis and Management of Diabetic Nephropathy; Abstract; Introduction; Diabetic Nephropathy; Proteomic Analysis of Diabetic Nephropathy; Proteomic Platforms and Methodologies; Two-Dimensional Gel Electrophoresis (2-De).
|
| 505 |
8 |
|
|a Liquid Chromatography Combined to Mass Spectrometry (Lc-Ms)Quantitative Proteomics; Sample Selection: Advantages and Disadvantages; Urine; Plasma; Lessons from Animal Models; Proteomics in the Clinical Setting: Biomarker Discovery; Conclusion and a Future Place in Therapy; References; Clinical Aspects of Diagnosis and Treatment of DN; Abstract; Introduction; Diagnosis; Clinical Manifestations; Adjunctive labs; Biopsy Indication [3, 15]; Treatment; 1. Lifestyle Modification; 2. Control of Glycated Hemoglobin (Goal of HbA1c: <7.0%); 3. Control of Blood Pressure (Goal of BP: <130/80 mmHg).
|
| 505 |
8 |
|
|a 4. Blockage of RAS5. Improvement in Dyslipidemia; 6. Novel Therapies; Conclusion; References; Diabetic Retinopathy; Abstract; Introduction; Pathophysiology; Classification; Symptoms and Signs; Screening and Diagnosis; Treatment; NPDR; PDR; References; Neurological Diseases in Diabetic Nephropathy; Abstract; Introduction; Central Nervous System Diseases; Uremic Encephalopathy; Dementia and Cognitive Impairment; Cerebrovascular Disease; Osmotic Myelinolysis; Movement Disorders and Restless Legs Syndrome; Opportunistic Infections; Neoplasms; Intracranial Hypotension; Intracranial Hypertension.
|
| 505 |
8 |
|
|a Peripheral Nervous System DiseasesUremic Polyneuropathy; Mononeuropathy; Uremic Myopathy; Autonomic Dysfunction; References; Diabetic Nephropathy and Nutrition; Abstract; Introduction; The Relationship between Nutritional Factors and Diabetic Nephropathy; Nutritional Recommendation for Patients with Diabetic Nephropathy (DN); Glycemic Control; Intake of Protein; Lipid Management; Restriction of Salt Intake; Vitamin D; Dietary Fiber; Dietary Pattern; Nutritional Consideration for End-Stage Renal Disease (ESRD); References; Renal Replacement Therapy in Diabetic Nephropathy; Abstract.
|
| 505 |
8 |
|
|a IntroductionWhen to Start Dialysis; How to Choose Dialysis; I. Long-Term Prognosis and Survival; II. Dialysis Adequacy; III. Residual Renal Function; IV. Complications; A. Cardiovascular Disease; B. Infection; C. Disturbance of Carbohydrate Metabolism and Glycemic Control; Conclusion; References; Clinical Trial Update on the Way to Cure DN; Abstract; Introduction; New Developments in Glycaemic Control and Blood Pressure Control; Glycaemic Control; Blood Pressure Control; New Approaches; Direct Renin Inhibitor; Inhibitors of AGE Formation; Endothelin Antagonists; Bardoxolone Methyl.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Diabetic nephropathies.
|
| 650 |
|
2 |
|a Diabetic Nephropathies
|
| 650 |
|
6 |
|a Néphropathies diabétiques.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Diabetic nephropathies.
|2 fast
|0 (OCoLC)fst00892229
|
| 700 |
1 |
|
|a Li, Mingxi,
|e editor.
|
| 700 |
1 |
|
|a Tao, Jianling,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Li, Mingxi.
|t Diabetic Nephropathy: From Bench to Bedside.
|d Hauppauge : Nova Science Publishers, Inc., ©2017
|z 9781536102772
|
| 830 |
|
0 |
|a Nephrology research and clinical developments series.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1488015
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4825333
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1488015
|
| 994 |
|
|
|a 92
|b IZTAP
|
